SiBone (NASDAQ:SIBN – Get Free Report) and Sintx Technologies (NASDAQ:SINT – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for SiBone and Sintx Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SiBone | 1 | 0 | 6 | 0 | 2.71 |
| Sintx Technologies | 1 | 0 | 3 | 0 | 2.50 |
SiBone presently has a consensus target price of $24.17, indicating a potential upside of 25.80%. Sintx Technologies has a consensus target price of $9.33, indicating a potential upside of 522.22%. Given Sintx Technologies’ higher possible upside, analysts plainly believe Sintx Technologies is more favorable than SiBone.
Risk and Volatility
Insider & Institutional Ownership
98.1% of SiBone shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 4.1% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares SiBone and Sintx Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SiBone | -6.85% | -8.23% | -6.07% |
| Sintx Technologies | -848.20% | -354.44% | -115.37% |
Earnings and Valuation
This table compares SiBone and Sintx Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SiBone | $213.60 million | 3.99 | -$18.90 million | ($0.34) | -56.50 |
| Sintx Technologies | $1.08 million | 5.97 | -$10.36 million | ($4.91) | -0.31 |
Sintx Technologies has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
SiBone beats Sintx Technologies on 9 of the 14 factors compared between the two stocks.
About SiBone
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
About Sintx Technologies
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
